Tissue-Level Mechanisms Responsible for the Increase in Bone Formation and Bone Volume by Sclerostin Antibody

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

(2013) Joy N Tsai et al.   LANCET

Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases

(2012) Hua Zhu Ke et al.   ENDOCRINE REVIEWS

Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts

(2012) Sang Wan Kim et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee

(2012) David W Dempster et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading

(2011) Xiaolin Tu et al.   BONE

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

(2010) Michael S Ominsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

(2010) Desmond Padhi et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones

(2010) Michael S Ominsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts

(2008) Robert L. Jilka et al.   BONE

Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis*

(2008) Xiaodong Li et al.   JOURNAL OF BONE AND MINERAL RESEARCH